Market Newsdesk

• ODD Follows RMAT Designation Granted to ALLO-715 by the U.S. Food and Drug Administration in Multiple Myeloma Patients
• Phase 1 Data from the ALLO-715 UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While Eliminating the Need for Bridging Therapy or Delays in Treatment Associated with Manufacturing
• Next Clinical Update from the ALLO-715 UNIVERSAL Trial Planned for Late 2021

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) to ALLO-715 for the treatment of multiple myeloma.

Initial results from the Phase 1 UNIVERSAL study of ALLO-715 in relapsed/refractory multiple myeloma were presented at an oral session of the American Society of Hematology annual meeting in December 2020. In April 2021, ALLO-715 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA). The UNIVERSAL trial continues to enroll patients to ALLO-715 including in combination with nirogacestat, a gamma secretase inhibitor from SpringWorks Therapeutics and in consolidation therapy.

“We are pleased to have received ODD for ALLO-715 just months after the FDA granted RMAT designation. These designations from the FDA underscore the importance of bringing this important therapeutic option to patients with multiple myeloma,” said Rafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene. “We look forward to presenting the next update from our UNIVERSAL trial by the end of 2021 and providing additional insight into the potential of our allogeneic cell therapy platform.”

Orphan-drug designation is granted by the FDA to a drug or biologic intended to treat a rare disease or condition, which generally includes a disease or condition that affects fewer than 200,000 individuals in the U.S. ODD granted therapies entitle companies to development incentives including tax credits for clinical testing, prescription drug user fee exemptions, and seven year marketing exclusivity in the event of regulatory approval. ODD does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.

About ALLO-715

ALLO-715, an AlloCAR T therapy targeting B-cell maturation antigen (BCMA), is a potential novel treatment for multiple myeloma and other BCMA-positive malignancies. Multiple myeloma originates in the bone marrow, and it is characterized by abnormalities in plasma cells that reproduce uncontrollably in the bone marrow and other disease sites. Multiple myeloma is incurable for most patients, as relapses occur despite most treatments available. Initial results from the Phase 1 UNIVERSAL study of ALLO-715 in relapsed/refractory multiple myeloma were presented in December 2020 at an oral session of the American Society of Hematology (ASH) annual meeting. In April 2021, ALLO-715 was granted Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA).

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to progress the UNIVERSAL trial and present any data from the trial; clinical outcomes, which may materially change as patient enrollment continues and more patient data become available; and the potential benefits of AlloCAR T™ therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended June 30, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

ALLO-715 utilizes TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at BCMA and holds all global development and commercial rights for this investigational candidate.

Allogene Media/Investor Contact:

Christine Cassiano
Chief Communications Officer
(714) 552-0326
[email protected]

WICHITA, Kan., Aug. 12, 2021 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE American: UAVS) (“AgEagle” or the “Company”), an industry-leading drone solutions provider, today announced that multiple, previously-disclosed lawsuits against the Company and certain of its current and former officers and directors have been dismissed.

As previously disclosed in the Company’s SEC filings, AgEagle and certain of its current and former officers and directors were named as defendants in two putative securities class actions filed in the U.S. District Court for the Central District of California (Lopez v. AgEagle Aerial Systems Inc., et al., Case No. 2:21-cv01810; and Madrid v. AgEagle Aerial Systems Inc., et al., Case No. 2:21-cv-01991). These matters were consolidated, and a Lead Plaintiff designated by Court Order. The Company is now pleased to report that on July 30, 2021, the Lead Plaintiff filed a voluntary dismissal of the consolidated securities class action.

Separately, two shareholders filed a derivative compliant on behalf of the Company and against certain of our current and former officers and directors before the Nevada federal court [Nostrand and Rickerson v. Mooney et al. (Defendants) and AgEagle Aerial Systems Inc., (Nominal Defendant), Case No. 3:21-cv-00130.]. AgEagle is pleased to report that on July 20, 2021, the Plaintiffs in this Nevada derivative action filed a voluntary dismissal of the action, and the court designated the case “closed” and “terminated.”

Finally, on July 27, 2021, a separate shareholder filed a similar derivative complaint on behalf of the Company and against certain of its current and former officers and directors in the U.S. District Court for the Central District of California (Granja v. AgEagle Aerial Systems Inc., et al, Case No. 2:21-cv-06056). AgEagle is pleased to report that on August 11, 2021, the Plaintiff in this California derivative action filed a voluntary dismissal of the action.

These dismissals resolve all known litigation against the Company and its officers and directors concerning Company operations.

About AgEagle Aerial Systems Inc.

Founded in 2010, AgEagle is one of the nation’s leading commercial drone technology providers. AgEagle’s mission is to empower The Drone Age^™ by providing American-made drone solutions to the world. The Company is leveraging its reputation as one of the industry’s premium technology solutions and aerial data intelligence providers to deliver high performance, end-to-end drone solutions for commercial use worldwide. AgEagle products are proudly manufactured and assembled in the United States. For additional information, please visit our websites at www.ageagle.com, www.measure.com and www.micasense.com.

Forward-Looking Statements


This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management’s current expectations include those risks and uncertainties relating to our competitive position, the industry environment, potential growth opportunities, and the effects of regulation and events outside of our control, such as natural disasters, wars or health epidemics. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

AgEagle Aerial Systems Contacts:

NEW ALBANY, Ohio, Aug. 12, 2021 (GLOBE NEWSWIRE) — abercrombie kids, a brand in the Abercrombie & Fitch Co. (NYSE: ANF) portfolio, has renewed its popular “Kind Crew” digital series for a second season, which is available now exclusively on Nickelodeon’s YouTube channel. The series continues to help inspire young people to make the world a more compassionate, understanding and kind place. It will feature a new cast of four phenomenal kids as well as special guests who can speak to important topics at hand – such as returning to school, how to leverage your uniqueness as your “superpower” and more.

Created in partnership with Nickelodeon and produced by Velocity, ViacomCBS’s branded content studio, the second season of the Kind Crew builds on its popular first season, which encouraged healthy conversations on topics such as addressing racism and the importance of voting. This year’s season aims to continue to support kids and empower them to discuss their feelings during times of change.

“We’re so proud to bring the Kind Crew back for a second season, and to continue to provide a space for kids and their families to discuss topics that impact kids’ daily lives,” said Carey Krug, SVP of Marketing at Abercrombie & Fitch. “We have all had to learn how to navigate this new ‘normal,’ which for kids, means returning to school while feeling a mix of joy and anxiety, particularly for those who were not physically in school last year. We hope the second season of the Kind Crew inspires kids to both share their feelings and support one another as we head back to school this year.”

In addition to appearing on the YouTube series, throughout the season, the new Kind Crew cast will engage with fellow kids via social media posts on their own channels and the abercrombie kids’ brand accounts. This year’s Kind Crew cast is made up of four kids who are nothing short of awesome: Keedron Bryant (@keedronbryant), Ava Clarke (@theavaclarke), Merrick Hanna (@merrickhanna) and Pressley Hosbach (@pressleyhosbach).

To meet the new Kind Crew cast and hear what they have to say about going back to school plus their own superpowers, watch the first two episodes of season 2 on Nickelodeon’s Youtube channel. And to keep up with all the kindness, make sure to follow abercrombie kids’ on Instagram at @abercrombiekids.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

A&F cautions that any forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) contained herein or made by management or spokespeople of A&F involve risks and uncertainties, and are subject to change based on various important factors, many of which may be beyond the Company’s control. Words such as “estimate,” “project,” “plan,” “believe,” “expect,” “anticipate,” “intend,” and similar expressions may identify forward-looking statements. Except as may be required by applicable law, we assume no obligation to publicly update or revise our forward-looking statements. Risks and uncertainties related to the duration and impact of the COVID-19 pandemic on the Company and the factors disclosed in “ITEM 1A. RISK FACTORS” of A&F’s Annual Report on Form 10-K for the fiscal year ended January 30, 2021 and in A&F’s subsequently filed quarterly reports on Form 10-Q, in some cases have affected, and in the future could affect, the company’s financial performance and could cause actual results for fiscal 2021 and beyond to differ materially from those expressed or implied in any of the forward-looking statements included in this press release or otherwise made by management. 

ABOUT ABERCROMBIE KIDS
 

A global specialty retailer of quality, comfortable, made-to-play favorites, abercrombie kids sees the world through kids’ eyes, where play is life and every day is an opportunity to be anything and better everything. 

abercrombie kids is a brand in the Abercrombie & Fitch Co. (NYSE: ANF) portfolio and is sold through more than 230 stores worldwide (includes Abercrombie & Fitch) and www.abercrombiekids.com globally. 

Media Contact:

Cory Weaver, Ph.D.
Abercrombie & Fitch
(614) 586-2717
[email protected] 

Business Media Contact:

Kara Page
Abercrombie & Fitch Co.
(614) 283-6192
[email protected]

Investor Contact:

Pam Quintiliano
Abercrombie & Fitch Co.
(614) 283-6877
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f4d2729a-c156-444f-9f02-51428abe1731

Launches TerraPay powered transfers to Senegal
and Benin

Newark, NJ, Aug. 12, 2021 (GLOBE NEWSWIRE) —

BOSS Revolution Money Transfer,
the international remittance service of IDT Corporation (NYSE: IDT), today announced a partnership with TerraPay, a global payments infrastructure company, to provide BOSS Revolution customers with new money transfer destinations across Africa, Asia, LATAM and Europe.

BOSS Revolution has begun offering seamless and secure payments to mobile wallets in Senegal and Benin through TerraPay to begin the expansion.

“Our customers in the US can now send money to friends and family in Senegal, Benin and 36 other countries including over 309,000 points of payment,” said Alfredo O’Hagan, IDT’s SVP for Consumer Payments. “We are delighted to partner with TerraPay as we open new corridors and emphasize real-time payment options leveraging their extensive platform.”

The BOSS Revolution Money Transfer service is readily available through the convenient BOSS Revolution Money app and its nationwide network of BOSS Revolution Money Transfer retailers. First time users of the app (free at App Store and Google Play) pay no fees on any transfer up to $300. BOSS Revolution Money Transfer is also available online or at any BOSS Revolution Money retailer.

As a B2B company, TerraPay connects multiple and diverse payment instruments and payment modes, with a single API integration – 4 Bn+ bank accounts, 500 Mn+ mobile wallets, and a large and diversified merchant ecosystem spanning across 79 receive countries and 153 send countries. With international remittances at the core, the company is embarking on creating unified payment rails for businesses and merchants across the globe. TerraPay’s endeavor is to strengthen and offer value-added services on its digital global payments highway, deepening engagement and adding more participants to a cohesive financial ecosystem.

Commenting on the relationship, Ani Sane, Co-founder and Chief Business Officer, TerraPay, said, “Our exciting partnership with BOSS Revolution will empower customers in the US to connect with family and friends worldwide, starting with mobile wallets in Senegal and Benin, while growing both companies’ footprints. This collaboration is another example of the impact our digital interoperable payment network provides across regions. We are driving greater access to financial services globally for all our partners and customers.”

About IDT Corporation:

IDT Corporation
(NYSE: IDT) is a global provider of fintech, cloud communications and traditional communications services. We make it easier for families to connect, support and share across international borders. We also enable businesses to transact and communicate with their customers with enhanced intelligence and insight.

Our BOSS Revolution branded money transfer and international calling services make sending money and speaking with friends and family around the world convenient and reliable. National Retail Solutions’ (NRS) point-of-sale retail network enables independent retailers to operate and process transactions more effectively while providing advertisers and consumer marketers with unprecedented reach into underserved consumer markets. net2phone’s unified communications as a service solution provides businesses with intelligently integrated cloud communications and collaboration solutions across channels and devices. Our IDT Carrier Services and IDT Express wholesale offerings enable communications companies to provision and manage international voice and SMS services.

About TerraPay:

TerraPay is a licensed digital payments infrastructure and solutions provider, paving the global payments highway. The company’s robust foundation and innovative platform technology serve as the digital interoperability engine enabling customers and businesses globally to send and receive payments on a secure, transparent, efficient, and real-time basis. The agile network supports diverse payment instruments and types of payments while adhering to complex regulations and compliance standards in different markets. For more information, please visit terrapay.com

Contact

:

Bill Ulrey
IDT Investor Relations
Phone: (973) 438-3838
E-mail: [email protected]

Promotion Recognizes Skilled Leadership and Contributions to MIMEDX’s Continued Growth

MARIETTA, Ga., Aug. 12, 2021 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced the promotion of Marion Snyder to Chief of Staff, Senior Vice President, Government Affairs. As a member of the Senior Leadership Team, Ms. Snyder will oversee strategic projects requiring cross-functional input, and drive the integration, effectiveness, and efficiency of decision making throughout the organization to advance multiple, company-wide initiatives. She will continue in her role as co-chair of the Company’s Inclusion and Diversity Council and serve as an important voice for MIMEDX’s government affairs and patient advocacy efforts. As a policy contributor and trusted advisor, she will serve as a significant communications link with the broader organization as a whole. With this promotion, the Company has commenced an executive search to fill Ms. Snyder’s prior role of Senior Vice President, Market Access.

Timothy R. Wright, MIMEDX Chief Executive Officer, said, “As leaders, we have an opportunity each day to make a difference for patients. I am confident that Marion’s experience, character, and leadership will help us continue our forward momentum to best meet the needs of our employees, customers, and patients. Our ability to deliver innovation that matters, focus on operational excellence, and hold ourselves accountable to each other enables all to achieve more.”

Ms. Snyder commented, “I look forward to working alongside Tim Wright and the MIMEDX leadership team on initiatives that increase patient access to evidence-based, regenerative technologies and elevate the standard of care. MIMEDX is a different company today, having accomplished a number of critical milestones that reflect sound business practices and an ethical culture, and position us for the future. I am excited to be a part of this incredible team at this time in MIMEDX’s history as we further our pipeline through innovation, elevate patient awareness about disease symptoms, and educate key stakeholders on the potential for our differentiated solutions to reduce cost to the healthcare system and restore quality of life.”

Ms. Snyder joined MIMEDX in 2013, and throughout her eight-year tenure she has continued to take on roles of increasing responsibility, most recently serving as Senior Vice President, Market Access. Her instincts and experience with customer contracting and reimbursement strategies, and overall market acumen have provided valuable expertise and leadership to advance a number of Company initiatives, and her reputation for cross-functional leadership is well appreciated.

Prior to joining MIMEDX, Ms. Snyder spent 13 years with Pfizer in a variety of roles, including Director of Payer Marketing for Enbrel, and started her career in sales and sales management with Johnson & Johnson. She earned her Bachelor of Science degree in Business Administration with a concentration in Marketing at Delaware Valley University.

About MIMEDX

MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts

Investors:

Jack Howarth
Investor Relations
404.360.5681
[email protected] 

Media:

Hilary Dixon
Corporate & Strategic Communications
770.651.9307
[email protected] 

Clinical Trials Continue Despite COVID-19 Restrictions 

Fremont, CA, Aug. 12, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — ABVC Biopharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (CNS), and ophthalmology, today announced its unaudited financial and operating results for the three-month period ended June 30, 2021.  

•  Revenues.We generated $31,441 and $226,513 in revenues for the three months ended June 30, 2021 and 2020, respectively; and incurred $646 and $4,236 in cost of sales for the three months ended June 30, 2021 and 2020, respectively. The decrease in revenues was mainly due to the impact of COVID-19 onto our CDMO business sector.   

•  Operating Expenses.  Our operating expenses have increased by $650,010, or 46%, to $2,066,310 for the three months ended June 30, 2021, from $1,416,290 for the three months ended June 30, 2020. Such increase in operating expenses was mainly due to the increase in selling, general and administrative expenses and research and development expenses.

Our selling, general and administrative expenses and stock-based compensation increased by $430,224, or 34%, mainly due to the increase in company’s marketing and up-list related expenses.

Our research and development expenses increased by $219,796 or approximately 158% primarily because of new service agreements signed with vendors during the three months ended June 30, 2021.

• 
  Other Income (Expense). 
  Our other expense was $77,005 for the three months ended June 30, 2021, as compared to $1,038,688 for the three months ended June 30, 2020. The change was principally caused by the decrease in impairment loss of $944,204 during the quarter, and increase in interest income and rental income, as well as decreasing loss on investment in equity securities, while deducted from decrease in net other income.

Interest income was $10,722 for the three months ended June 30, 2021, as compared to $9,350 for the three months ended June 30, 2020. The increase of $1,372, or approximately 15%, was primarily due to the interest income for various related-party loans.

Loss on investment in equity securities was $53,591 for the three months ended June 30, 2021, as compared to $109,656 for the three months ended June 30, 2020. The decrease of $56,065, or approximately 51%, was primarily due to the loss on investment in BioFirst. 

Other income and government grant income totaled $162 for the three months ended June 30, 2021, as compared to $170,179 for the three months ended June 30, 2020. The decrease of $170,017, or approximately 100%, was primarily due to the tax refund for greenlight project recorded in the first half year of 2020.  

• 
  Net Loss.
   As a result of the above factors, our net loss was $2,052,956 for the three months ended June 30, 2021, compared to $2,184,057 for the three months ended June 30, 2020, representing a decrease of $131,101, or 6%.

“In spite of elevated COVID-19 restrictions, we were pleased to make significant clinical study progress during Q2 with respect to Vitargus, our medical device, and MDD for Cancer Patients, our depression medicine for cancer patients,” said Dr. Howard Doong, ABVC BioPharma’s chief executive officer.“For example, we identified three potential trial sites and principal investigators in Australia to conduct further clinical trials of Vitargus beginning in Q4 of this year, the data of which may be included in the pivotal trial phase required by the US FDA to obtain marketing approval. And, in connection with our medicine addressing depression for cancer patients, MDD for Cancer Patients, we submitted all necessary protocol documents to Cedar-Sinai Medical Center that we believe will enable them to issue their final approval to initiate clinical trial Phase I/II for this drug before the end of 2021.” 

Dr. Doong continued, “We also took steps during the quarter to expand our patent protection for our medicines that address MDD andAttention Deficit/Hyperactivity Disorderby applying for additional patents in both the United States and China that include the results of the Phase II human trials for these medicines.”

Subsequent to the quarter, the company completed a public offering of 1,100,000 units, consisting of 1,100,000 shares of its common stock, Series A Warrants to purchase up to 1,100,000 shares of common stock at $6.30 per share and Series B Warrants to purchase up to 1,100,000 shares of common stock at $10.00 per share, resulting in net proceeds to ABVC BioPharma of $6,021,585, after deducting the underwriting commissions and offering expenses payable by us. We intend to use the net proceeds from the offering to fund clinical trials and for working capital and general business purposes. In addition, while we have not entered into any agreements, commitments or understandings relating to any significant transaction, we may use a portion of the net proceeds to pursue acquisitions, joint ventures, and other strategic transactions.

The Company’s common stock began trading on The Nasdaq Capital Market on August 3, 2021,under the ticker symbol “ABVC”. 

About ABVC Biopharma

ABVC Biopharma is a clinical-stage biopharmaceutical company focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center). The company has an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development.
Disclaimer
Clinical trials are in early stages, and there is no guarantee that any specific outcome will be achieved. Past performance is not indicative of future results. Investments may be speculative and illiquid, and there is a risk of complete loss. 
Forward-Looking Statements
Clinical trials are in early stages, and there is no guarantee that any specific outcome will be achieved. This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Contact:

Andy An – Chief Financial Officer
765-610-8826
[email protected]

ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

ABVC BIOPHARMA, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS 
FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020
(UNAUDITED)